Get the latest tech news
Novo’s Diabetes Drug Shows Mixed Results in Alzheimer’s
Novo Nordisk A/S’s diabetes drug Victoza yielded mixed results in a mid-stage study of Alzheimer’s disease, failing to meet its primary goal while showing hints that larger trials of similar drugs may be successful.
Novo Nordisk’s diabetes drug Victoza.Photographer: Tripplaar Kristoffer/Sipa/AP Photo
Or read this on Bloomberg
